UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-38634 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 85 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, par ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the quarterly period ended June 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 For the transition period from to Commission File Number: 001-38634 Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4306526 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4306526 (State o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38634 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 85-4306526 (State or other jurisdiction of ...

Financial Performance - Reviva Pharmaceuticals has an accumulated deficit of $63.1 million as of September 30, 2021, with a net loss of approximately $4.8 million for the nine months ended September 30, 2021[73]. - The company has not generated any revenues from product sales and has never been profitable[73]. - The net loss for the nine months ended September 30, 2021, was approximately $4.8 million, compared to a net loss of $2.3 million for the same period in 2020[92]. - The company reported a gain on remeasurement of warrant liabilities of approximately $1.3 million for the nine months ended September 30, 2021, resulting from a decline in stock price[95]. - Net cash provided by financing activities for the nine months ended September 30, 2021, was approximately $31.5 million, primarily from a public offering[105]. - Net cash used in operating activities for the nine months ended September 30, 2021, was approximately $6.8 million, primarily due to a net loss and changes in operating assets[103]. Research and Development - The lead drug candidate RP5063 is ready for continued clinical development for multiple neuropsychiatric indications, including schizophrenia and bipolar disorder, with a focus on initiating a pivotal Phase 3 study in acute schizophrenia[65][78]. - RP5063 has completed Phase 1 studies for several indications, including major depressive disorder and attention deficit hyperactivity disorder[78]. - The second drug candidate, RP1208, has completed pre-clinical development studies and is ready for IND enabling studies for depression and obesity[78]. - Research and development expenses are expected to increase significantly as the company advances its development programs and prepares for potential commercialization[77]. - Research and development expenses increased by approximately $1.4 million, or 148,943%, for the three months ended September 30, 2021, compared to the same period in 2020, primarily due to higher drug development costs and salary expenditures[87]. - The estimated initial costs for conducting the Phase 3 clinical study for RP5063 are approximately $21.0 million, with payments scheduled over 2021 to 2023[81]. Operational Expenses - General and administrative expenses rose to approximately $1.1 million for the three months ended September 30, 2021, reflecting an increase of $542,000, or 106%, mainly due to higher salaries and insurance costs[88]. - The company expects general and administrative expenses to increase as it expands infrastructure and continues clinical program development[83]. Capital Requirements - Reviva Pharmaceuticals has cash of approximately $33.5 million as of September 30, 2021, but will need to raise additional capital to fund its operations beyond December 2022[75]. - The company does not currently have any committed external sources of capital and may need to raise additional funds through equity or debt financings[98]. Impact of COVID-19 - The impact of the COVID-19 pandemic may adversely affect clinical trials, including patient recruitment and dosing[68]. Future Plans - Reviva Pharmaceuticals plans to seek regulatory and marketing approvals for its product candidates and establish a sales and marketing infrastructure[74].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4306526 (State or ...

Financial Performance - Reviva Pharmaceuticals has an accumulated deficit of $59.3 million as of March 31, 2021, and reported a net loss of approximately $949,000 for the three months ended March 31, 2021[88]. - The net loss for the three months ended March 31, 2021, was approximately $949,000, compared to a net loss of $749,000 for the same period in 2020[101]. - Net cash used in operating activities for Q1 2021 was approximately $3.1 million, significantly higher than $61,000 in Q1 2020, primarily due to increased net operating assets[112]. - The gain on remeasurement of warrant liabilities for Q1 2021 was approximately $923,000, resulting from a decrease in calculated fair value due to a decline in stock price[105]. - As of March 31, 2021, the company had cash of approximately $5.6 million and expects to incur significant expenses and operating losses in the foreseeable future[106]. Research and Development - The company expects to incur significant expenses and increased operating losses for the next several years as it continues to develop its product candidates[88]. - Reviva Pharmaceuticals has two drug candidates in its pipeline: RP5063 (Brilaroxazine) and RP1208, both of which have been granted composition of matter patents in the U.S., Europe, and other countries[79]. - RP5063 is in Phase 2 clinical development for acute schizophrenia and has completed Phase 1 studies for multiple indications, including bipolar disorder and major depressive disorder[93]. - The company anticipates that its research and development expenses will increase significantly as it advances its development programs and prepares for potential commercialization[92]. - Research and development expenses increased by approximately $120,000, or 44%, from $271,000 in Q1 2020 to $391,000 in Q1 2021, primarily due to higher salary expenditures and increased consulting costs[102]. Operational Challenges - Reviva Pharmaceuticals has taken precautionary measures in response to COVID-19, which may disrupt clinical trials and operations[82]. - The company does not currently have any committed external sources of capital and may need to finance cash needs through equity or debt financings[107]. Future Plans - The company is focusing on completing the clinical development of RP5063 for various neuropsychiatric and respiratory indications, subject to additional financing[81]. - The estimated initial costs for conducting the Phase 3 clinical study for RP5063 are approximately $21.0 million, with $7.0 million payable in 2021, $10.0 million in 2022, and $4.0 million in 2023[96]. - The company plans to establish a sales, marketing, and distribution infrastructure to commercialize any drugs that receive marketing approval[89]. - The company expects general and administrative expenses to increase as it expands infrastructure and continues clinical program development[98]. Administrative Expenses - General and administrative expenses rose by approximately $1.1 million, or 327%, from $347,000 in Q1 2020 to $1.5 million in Q1 2021, driven by increased use of consultants and higher insurance costs[103]. - The company incurred no interest expense in Q1 2021, a decrease from approximately $130,000 in Q1 2020, due to the conversion of all investor notes prior to the Business Combination[104].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 (Exact name of registrant as specified in its charter) Delaware 85-4306526 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 19925 Stevens Creek Blvd., Suite 100 Cupertino, CA 95014 95014 (Address of principal executive offices) (Zip c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 28, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 TENZING ACQUISITION CORP. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(g) ...